Alphatec Holdings, Inc. (NASDAQ:ATEC) Given Average Rating of “Moderate Buy” by Brokerages

Alphatec Holdings, Inc. (NASDAQ:ATEC) has received a consensus rating of “Moderate Buy” from the twelve brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and ten have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $22.8182.

Several equities analysts recently issued reports on ATEC shares. Wall Street Zen upgraded Alphatec from a “hold” rating to a “buy” rating in a report on Saturday, January 31st. Weiss Ratings restated a “sell (e+)” rating on shares of Alphatec in a research report on Monday, December 29th. HC Wainwright reaffirmed a “buy” rating and issued a $24.00 target price on shares of Alphatec in a research note on Monday, January 12th. Piper Sandler reissued an “overweight” rating and set a $25.00 price target (up from $20.00) on shares of Alphatec in a research note on Friday, October 31st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Alphatec in a research note on Monday, January 12th.

Alphatec Price Performance

ATEC opened at $13.82 on Monday. The company has a debt-to-equity ratio of 43.02, a current ratio of 1.99 and a quick ratio of 1.24. The stock has a market capitalization of $2.05 billion, a P/E ratio of -13.29 and a beta of 1.01. The company’s 50 day simple moving average is $18.85 and its 200-day simple moving average is $17.01. Alphatec has a one year low of $8.81 and a one year high of $23.29.

Insider Buying and Selling at Alphatec

In other Alphatec news, major shareholder Jennifer N. Pritzker sold 250,000 shares of the firm’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $20.62, for a total transaction of $5,155,000.00. Following the transaction, the insider owned 10,895,045 shares in the company, valued at approximately $224,655,827.90. This trade represents a 2.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David R. Pelizzon sold 250,000 shares of the company’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $20.62, for a total value of $5,155,000.00. Following the completion of the sale, the director directly owned 10,895,045 shares of the company’s stock, valued at approximately $224,655,827.90. This trade represents a 2.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 3,031,125 shares of company stock valued at $62,311,578. 20.90% of the stock is currently owned by company insiders.

Institutional Trading of Alphatec

A number of large investors have recently made changes to their positions in the company. Aster Capital Management DIFC Ltd acquired a new position in Alphatec in the third quarter valued at about $34,000. Osterweis Capital Management Inc. bought a new position in shares of Alphatec during the 2nd quarter valued at about $37,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Alphatec in the 3rd quarter valued at approximately $73,000. FNY Investment Advisers LLC bought a new stake in Alphatec during the 3rd quarter worth approximately $74,000. Finally, Nisa Investment Advisors LLC raised its holdings in Alphatec by 22.4% during the 2nd quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock worth $63,000 after buying an additional 1,045 shares during the period. Institutional investors own 66.35% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.